Zymeworks Inc. (ZYME)

Over the past year as of April 10, 2026, Zymeworks' stock has surged 190%. Key events include the appointments of Adam Schayowitz as Head of R&D and Scott Platshon as Chief Business Officer on April 9, 2026, and Kristin Stafford as the new CFO on April 1, 2026. The FDA granted Fast Track Designation to ZW191 for advanced or metastatic platinum-resistant ovarian cancer on March 30, 2026. Zymeworks announced presentations for Ziihera® at the 2026 AACR Annual Meeting on March 18, 2026. On March 4, 2026, the company reported its Q4 2025 earnings, missing consensus EPS expectations but improving FY25 profitability, and secured $250 million in royalty-backed financing with Royalty Pharma. Positive Phase 3 results for Ziihera® in first-line HER2-positive gastroesophageal adenocarcinoma were presented at ASCO GI on January 11, 2026. In November 2025, Zymeworks announced a $125.0 million share repurchase plan. H.C. Wainwright reiterated a Buy rating with a $46.00 price target, and Stifel raised its price target to $47, maintaining a Buy rating on April 10, 2026.

Demand for Zymeworks' products and services is primarily driven by medical need, clinical trial outcomes, and regulatory approvals, rather than seasonal factors. Demand is expected to be relatively consistent, dictated by disease prevalence and the successful development and commercialization of its biotherapeutics.

Zymeworks, Inc. is a global biotechnology company focused on discovering, developing, and commercializing novel biotherapeutics for difficult-to-treat diseases like cancer, inflammation, and autoimmune conditions. The company's therapeutic work is built around platforms like Azymetric™, Drug Conjugate Platforms, EFECT™, and ProTECT™, enabling the engineering of antibody-based therapeutics, including bispecific and multispecific antibodies and antibody-drug conjugates (ADCs). Key product candidates include Zanidatamab (Ziihera®), Zanidatamab zovodotin, ZW191, Pasritamig, and other preclinical candidates like ZW171, ZW220, and ZW251.

Zymeworks is headquartered in Vancouver, British Columbia, Canada, with R&D facilities in Vancouver and Seattle. Manufacturing is supported through partnerships with contract manufacturing organizations across North America and Asia. The company has a commercial presence in key international markets, particularly in Asia-Pacific, and has expanded its early-stage development team into Dublin, California, and Singapore. Zymeworks aims to further expand its presence in key markets, including North America, Europe, and Asia, through partnerships and direct commercialization efforts.

Zymeworks' brand reputation appears positive, reflected in a "Moderate Buy" consensus rating from analysts and a 190% stock surge over the past year. Analysts cite the company's diversified oncology pipeline, proprietary platforms, global partnerships, and growth potential. While Q4 2025 earnings showed a miss on GAAP EPS and a revenue decline, the company improved FY25 profitability and maintained strong liquidity. The $250 million royalty financing and FDA Fast Track Designation for ZW191 further contribute to a favorable perception.

Zymeworks, Inc. has significant institutional ownership, ranging from 87.61% to 92.89%. Major institutional owners include EcoR1 Capital, LLC, Rubric Capital Management LP, BlackRock, Inc., Bvf Inc/il (BVF Partners L.P.), Perceptive Advisors Llc, Morgan Stanley, Vanguard Group Inc (The Vanguard Group, Inc.), BNP Paribas Asset Management Holding S.A., Siren, L.L.C., Deutsche Bank Ag, State Street Corp., Silvercrest Asset Management Group, Inc., and Manulife Financial Corp. Insiders hold a notable percentage of the stock, ranging from 33.51% to 90.32%, with Ecor1 Capital LLC being the largest individual shareholder.